clinical trial · NCT07153471
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Eli Lilly and Company·phase3·recruiting·n = 800
OsteoarthritisOrforglipronPlacebo
brief summary
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
started
Sep 15, 2025
primary completion
Apr 1, 2028
completion
May 1, 2028
last updated
Apr 17, 2026
official title
A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol